Related Experiment Videos
Vigabatrin as first line therapy in infantile spasms: review of seven patients
1Department of Paediatrics, Tuen Mun Hospital, New Territories, Hong Kong.
Insights
Vigabatrin shows promise as an effective first-line treatment for infantile spasms, with significant seizure reduction observed in most patients within one week. This study suggests vigabatrin monotherapy is well-tolerated and can be evaluated within two weeks.
Area of Science:
- Pediatric Neurology
- Epileptology
Background:
- Infantile spasms are a severe epilepsy syndrome in infants.
- Early diagnosis and treatment are crucial for optimal neurodevelopmental outcomes.
Purpose of the Study:
- To evaluate the efficacy of vigabatrin as an initial monotherapy for infantile spasms.
- To determine the optimal duration for assessing vigabatrin's effectiveness.
Main Methods:
- A retrospective review of seven infants diagnosed with new-onset infantile spasms.
- Vigabatrin administered as initial monotherapy at 50-100 mg/kg/day.
- Efficacy assessed at the two-week mark.
Main Results:
- Significant seizure reduction occurred in 4 out of 7 patients.
- Two patients experienced 50-75% seizure reduction.
- Efficacy was evident within the first week for 5 responding patients.
- No adverse effects were reported.
Conclusions:
- Vigabatrin is a viable first-line treatment option for infantile spasms.
- A two-week treatment period appears sufficient to gauge vigabatrin's efficacy.
- Vigabatrin monotherapy was well-tolerated, allowing continuation in most cases.
Objective:
To study the efficacy of vigabatrin as initial therapy in infantile spasms.
Methodology:
We reviewed seven patients with newly diagnosed infantile spasms referred to Tuen Mun Hospital, Hong Kong from 1994 to 1995. Vigabatrin was given as the initial monotherapy at therapeutic dose of 50-100 mg/kg. Efficacy was evaluated at the end of second week of treatment.
Results:
Significant improvement was observed in four patients, 50-75% seizure reduction in two and no response in one patient. Efficacy was noted within the first week of treatment in five of the six patients who responded. No adverse effects were observed. Vigabatrin monotherapy could be continued in five patients.
Conclusion:
Vigabatrin could be considered as the first line treatment in infantile spasms. A period of 2 weeks may be sufficient to evaluate its efficacy.